SEC Form 4 · accession 0001209191-18-038641
Orthofix Medical Inc. · OFIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Finegan
Officer — Chief Strategy Officer
Period of report
Jun 18, 2018
Accepted (ET)
Jun 19, 2018 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000884624
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 18, 2018 | M | 10,000 | $28.95 | A | 46,844 | D | |
| Common Stock | Jun 18, 2018 | M | 20,000 | $25.01 | A | 66,844 | D | |
| Common StockF3 | Jun 18, 2018 | S | 19,275 | $58.6341 | D | 47,569 | D | |
| Common StockF4 | Jun 18, 2018 | S | 10,725 | $59.1262 | D | 36,844 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $28.95 | Jun 18, 2018 | M | 10,000 | D | Jun 30, 2011 | Jun 30, 2018 | Common Stock | 10,000 | 0 | D |
| Stock Option (right to buy) | $25.01 | Jun 18, 2018 | M | 20,000 | D | Jul 25, 2012 | Jul 25, 2019 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2018.
- F2The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2018.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.01 to $59.00, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.01 to $59.13, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.